Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cadonilimab plus docetaxel in advanced non-small cell lung cancer after failure of PD-1/PD-L1 inhibitor and platinum-doublet chemotherapy
CTR20220520Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc.. Started May 2022; status: active.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220520.